FCGBPは,JAK2 / STAT3 / c-Myc経路を調節することにより,グリオマの成長を促進します
Jin Zheng1, Yu Xin Rao1, Hui Zheng2
1Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Cancer medicine
|February 15, 2026
まとめ
補完体C1G結合タンパク質 (FCGBP) のFc断片は,膠原腫の進行を促進し,予後不良に関連しています. このFCGBPによるJAK2/STAT3経路の活性化により,その経路が潜在的治療標的となる可能性が示唆されている.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- がん研究 がん研究
背景:
- 補完体C1G結合タンパク質 (FCGBP) のFc断片は,様々な癌に関与しています.
- 膠原腫の発生と進行におけるFCGBPの特定の役割については,さらなる解明が必要である.
研究 の 目的:
- 膠原腫におけるFCGBPの発現と機能を調査する.
- FCGBPとグリオマ患者のアウトカムとの関連を判断する.
- JAK2/STAT3経路を含む基礎となる分子メカニズムを探求する.
主な方法:
- 定量的リアルタイムPCR (qRT-PCR),ウェスタン・ブロッティング (Western blotting, WB),および免疫ヒスト化学 (IHC) を用いて,FCGBP発現を評価した.
- 機能分析と動物モデルを用いて,FCGBPが膠原腫における役割を研究した.
- FCGBPがジャヌスキナーゼ2/シグナルトランスデューサーおよびトランスクリプション3のアクティベーター (JAK2/STAT3) 経路に及ぼす影響も調査した.
主要な成果:
- FCGBPは,膠原腫組織で著しく過剰発現していることが判明しました.
- FCGBP濃度の上昇は,より高い腫瘍グレードと,より悪い臨床結果と相関していた.
- FCGBPは,JAK2/STAT3シグナル伝達経路の活性化により,膠原腫細胞の攻撃性を促進する.
結論:
- FCGBPは,膠原腫の攻撃性を高め,予後が悪いことにも貢献する上で重要な役割を果たします.
- FCGBPは,膠原腫治療の潜在的な治療目標です.
関連する概念動画
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
PI3K/mTOR/AKT Signaling Pathway
5.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.7K
TGF - β Signaling Pathway
10.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.6K
The JAK-STAT Signaling Pathway
13.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.1K
Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K


